Evaluation for Potential Drug–Drug Interaction of MT921 Using In Vitro Studies and Physiologically–Based Pharmacokinetic Models
MT921 is a new injectable drug developed by Medytox Inc. to reduce submental fat. Cholic acid is the active pharmaceutical ingredient, a primary bile acid biosynthesized from cholesterol, endogenously produced by liver in humans and other mammals. Although individuals treated with MT921 could be adm...
Main Authors: | Hyo-jeong Ryu, Hyun-ki Moon, Junho Lee, Gi-hyeok Yang, Sung-yoon Yang, Hwi-yeol Yun, Jung-woo Chae, Won-ho Kang |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/7/654 |
Similar Items
-
Erythrina moths Terastia meticulosalis Guenée and Agathodes designalis Guenée
by: Andrei Sourakov
Published: (2012-03-01) -
Application of the Population Pharmacokinetics Model-Based Approach to the Prediction of Drug–Drug Interaction between Rivaroxaban and Carbamazepine in Humans
by: Lien Thi Ngo, et al.
Published: (2023-05-01) -
Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes
by: Yiting Yang, et al.
Published: (2020-09-01) -
Pharmacokinetics and metabolism in drug design /
by: 464017 Smith, Dennis A., et al.
Published: (2006) -
Basic Mold Prevention
by: Hyun-Jeong Lee, et al.
Published: (2007-03-01)